Incyte's Ruxolitinib Shows Better Outcomes Regardless Of Organs Affected In GvHD Patients

Incyte Corporation INCY has announced that positive data from the Phase 3 REACH3 study have been published in The New England Journal of Medicine (NEJM). The study is jointly sponsored by Incyte and Novartis AG NVS.
The publication includes data showing Jakafi (ruxolitinib) significantly improved overall response rate at Week 24 (49.7% vs. 25.6%) with a higher best overall response rate (76.4% vs. 60.4%) vs. best available therapy (BAT) in patients with steroid-refractory/dependent chronic graft-versus-host disease (GvHD).
In addition, a new subgroup analysis included in the publication found that patients on ruxolitinib had better outcomes regardless of the individual organs affected at baseline.
No new safety signals were observed in REACH3, and adverse events attributable to treatment were consistent with the known safety profile of ruxolitinib.
Mortality rates were similar across treatment arms (18.8% in the ruxolitinib arm vs. 16.5% in the BAT arm).
Deaths reported primarily due to chronic GVHD complications or treatment were higher in the ruxolitinib vs. BAT arms (13.3% vs. 7.9%, respectively).
The U.S. application is currently under review, with a target action date of September 22, 2021.
Price Action: INCY shares closed at $79.87 on Wednesday.